Onyx ONE Study; A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients

• Age ≥ 75 years old

• Any prior documented intracerebral bleed

• Any documented stroke in the last 12 months

• Hospital admission for bleeding during the prior 12 months

• Non-skin cancer diagnosed or treated ≤3 years

• Planned surgery within the next 12 months

• Renal failure defined as: Creatinine clearance \<40 ml/min

• Thrombocytopenia (PLT \<100,000/mm3)

• Severe chronic liver disease defined as: subjects who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice